DexCom, Inc.
DXCM
株式のランク
#757
DexCom, Inc. is a medical technology company primarily focused on innovating,... DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
株価
$85.72
最終同期: 2026-10-20
時価総額
$32.35B
変化（1日）
-0.30%
変化（1年）
22.90%
国
US
取引 DexCom, Inc. (DXCM)
カテゴリー
Healthcare
DexCom, Inc.（DXCM）のP/E比率
October 2026 時点のP/E比率 TTM 32.23
DexCom, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は 32.23 です。2023 年末時点での P/E は 88.46 でした。
DexCom, Inc. の P/E 比率の履歴（2000 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 32.23 | -40.99% |
| 2024 | 54.61 | -38.26% |
| 2023 | 88.46 | -31.56% |
| 2022 | 129.24 | -46.03% |
| 2021 | 239.45 | 238.65% |
| 2020 | 70.71 | -64.13% |
| 2019 | 197.12 | -337.11% |
| 2018 | -83.13 | -15.75% |
| 2017 | -98.68 | 29.66% |
| 2016 | -76.11 | -32.94% |
| 2015 | -113.49 | -38.58% |
| 2014 | -184.78 | 118.77% |
| 2013 | -84.46 | 392.67% |
| 2012 | -17.14 | 25.47% |
| 2011 | -13.66 | -2.87% |
| 2010 | -14.07 | 110.14% |
| 2009 | -6.69 | 353.93% |
| 2008 | -1.47 | -72.97% |
| 2007 | -5.46 | -5.53% |
| 2006 | -5.77 | -37.14% |
| 2005 | -9.19 | 376.58% |
| 2004 | -1.93 | -25.11% |
| 2003 | -2.57 | -17.56% |
| 2002 | -3.12 | -12.19% |
| 2001 | -3.56 | -30.59% |
| 2000 | -5.12 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 33.11 | 2.74% |
US
|
|
| 21.39 | -33.64% |
IE
|
|
| 28.94 | -10.19% |
US
|
|
| 17.34 | -46.20% |
US
|
|
| - | - |
DE
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。